Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



This 6-yielding U.S. pharma giant is a safe hold - The Globe and Mail

November 11, 2024
Pfizer Inc. (NYSE:PFE) is a leading pharmaceutical company that continues to show promise in the market. With its strong portfolio of drugs and research, investors are heavily searching for Pfizer as a potential investment. The company's position has recently been raised by Costello Asset Management INC, indicating their confidence in its future performance. Additionally, Pfizer's relative strength alert suggests favorable movement in its stock price. With a 6% yield, Pfizer is considered a safe hold for both short-term and long-term investors. To make informed decisions about the movement of Pfizer's stocks, it is recommended to consult professionals from Stocks Prognosis.

Find out how the PFIZER INC. rate is expected to change

Get Forecast for PFE

Investor opinions & comments:

I'm glad to hear that Costello Asset Management INC is confident in Pfizer's future performance. It gives me more reassurance as an investor
— from IsaacPerry at 11-14-2024 08:55
This is great news! I've been considering investing in the pharma industry and Pfizer seems like a solid choice with its strong portfolio and research
— from LillianBell at 11-13-2024 15:42
Pfizer's relative strength alert is definitely a positive sign. I'll keep a close eye on their stock price
— from FinanceFelix at 11-13-2024 14:41
Pfizer has a strong reputation in the pharmaceutical industry, and their research capabilities are impressive. I have confidence in their ability to continue developing innovative drugs
— from DavidWilson at 11-13-2024 09:33
I'm not convinced about Pfizer's long-term prospects. The pharmaceutical industry is constantly evolving, and there might be new competitors or regulatory challenges that could impact their success
— from FinanceFelix at 11-13-2024 08:25
Pfizer's 6% yield is quite attractive, especially in a low-interest-rate environment. It provides a nice source of income for investors
— from LaylaFloyd at 11-12-2024 15:17
I've been a long-term investor in Pfizer, and it has consistently provided solid returns. Its diverse portfolio helps mitigate risks
— from MoneyMartha at 11-12-2024 05:17
I'm concerned about Pfizer's heavy reliance on its drug portfolio. If one of their key drugs loses patent protection or faces generic competition, it could significantly impact their revenue
— from NatalieBaker at 11-11-2024 18:33
I'm not convinced that Pfizer's 6% yield makes it a safe hold. The pharma industry can be volatile, and there's no guarantee that the stock price will remain stable
— from NoraJenkins at 11-11-2024 10:51
If you want to leave a comment, then you need Login or Register





Other news for PFE

PFEJune 12, 2025PFIZER INC. Hits Price Target Forecast with 7.16% Profit  ~2 min.

On May 28, 2025, QuantWave, an automated forecasting platform, released a long signal for PFIZER INC. stock when it was trading at $23.18....

PFEJune 11, 2025PFIZER INC. Hits Price Target Forecast with 6.25% Profit, Validating QuantWave's Analytics  ~1 min.

PFIZER INC. has successfully reached the price target forecast set by QuantWave, signaling a profitable long position. The forecast signal was issued on 2025-05-21 when the stock was at 23.04 $....

PFEJune 10, 2025PFIZER INC. Hits Price Target Forecast with 5.47% Profit - QuantWave Prediction Success  ~1 min.

On May 22, 2025, QuantWave, the automated forecasting platform, issued a long signal for PFIZER INC. (PFE) at a price of 23.04 $....

PFEJune 6, 2025PFIZER INC. PFE Partners with Acepodia, Innovating Cancer Treatments  ~1 min.

Pfizer Inc. announced a new partnership with Acepodia to develop cutting-edge cancer treatments....

PFEApril 4, 2025PFIZER INC. Hits Forecast Price Target with 7.0% Profit - QuantWave Analysis  ~1 min.

PFIZER INC. has successfully achieved the price target forecast set by QuantWave, with a profit of 7.0%. The forecast signal was issued on April 2, 2025, at a price of 24.24 $....



Related news

VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....

REGNJanuary 2, 2025Regeneron Pharmaceuticals Continues to Impress Investors with Strong Returns  ~1 min.

In the past five years, Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered a solid return of 89%, making it a favorable choice for investors....

REGNFebruary 10, 2025Regeneron Pharmaceuticals Inc REGN Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... Yahoo Finance  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) recently held its Q4 2024 earnings call, highlighting strong revenue growth and positive developments in its portfolio....

REGNMarch 16, 2025JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC.  ~2 min.

In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN)....

VRTXMarch 22, 2025Vertex Pharmaceuticals VRTX: One of the Best Biotech Stocks to Buy According to Billionaires  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) has been recognized as one of the top biotech stocks to invest in by billionaires....